MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
24.56
-0.08
-0.32%
After Hours: 24.56 0 0.00% 17:47 04/08 EDT
OPEN
24.94
PREV CLOSE
24.64
HIGH
25.38
LOW
24.20
VOLUME
1.73M
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
8.58
MARKET CAP
2.17B
P/E (TTM)
-7.4539
1D
5D
1M
3M
1Y
5Y
1D
Abeona appoints Syndax CFO Keith Goldan to board as audit committee chair
Reuters · 1d ago
Weekly Report: what happened at SNDX last week (0330-0403)?
Weekly Report · 2d ago
Syndax grants inducement stock options for up to 228,500 shares to new hires
Reuters · 5d ago
SYNDAX PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Barchart · 5d ago
Most and least shorted mid-to mega-cap healthcare stocks in March
Seeking Alpha · 5d ago
Kura Oncology: Commercialization In AML Presents Asymmetric Upside
Seeking Alpha · 6d ago
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After An 84% One Year Share Price Jump
Simply Wall St · 04/02 06:30
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.